What is a characteristic of Cooley's anemia (Beta-Thalassemia Major)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Cooley's anemia (Beta-Thalassemia Major) is characterized by severe reduction or absent production of the β-globin chain constituent of hemoglobin (Hb) A, resulting in ineffective erythropoiesis and profound anemia.

Key Characteristics

  • Ineffective erythropoiesis caused by an excess of α-globin chains
  • Profound anemia that is life-threatening from ≈1 to 2 years of age 1
  • Requirement for lifelong blood transfusions, with a broad phenotypic characterization of >8 transfusion events per year in an adult aged >16 years 1
  • Increased risk of iron-related complications due to iron overload from transfusions, necessitating lifelong iron chelation treatment 1

Clinical Implications

  • Heart failure is the most common cause of death in TM, primarily resulting from cardiac iron accumulation 1
  • Diagnosis of ventricular dysfunction in TM patients is complicated by cardiovascular adaptation to chronic anemia, requiring estimation of cardiac iron by cardiac T2* magnetic resonance 1

From the Research

Characteristics of Cooley's Anemia (Beta-Thalassemia Major)

  • Cooley's anemia, also known as Beta-Thalassemia Major, is a severe form of beta thalassemia that requires lifelong transfusions starting in early childhood, often before two years of age 2.
  • It is characterized by a complete lack of beta protein in the hemoglobin, causing a life-threatening anemia that requires regular blood transfusions and extensive ongoing medical care 3.
  • The condition leads to iron-overload due to extensive blood transfusions, which must be treated with chelation therapy to prevent early death from organ failure 3, 4.
  • Patients with Beta-Thalassemia Major become severely anemic by 6 to 18 months of age and are transfusion dependent for life 5.
  • Bone marrow expansion and extramedullary hematopoiesis are common complications of the disease, which can lead to morbidities affecting the skeletal system, endocrine organs, heart, and liver 2.
  • The clinical severity of Beta-Thalassemia Major is related to the extent of imbalance between the alpha and nonalpha globin chains 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Alpha- and Beta-thalassemia: Rapid Evidence Review.

American family physician, 2022

Research

Management of thalassemia major (Cooley's anemia).

Hematology/oncology clinics of North America, 1991

Research

Genetic therapy for beta-thalassemia: from the bench to the bedside.

Hematology. American Society of Hematology. Education Program, 2010

Research

Beta-thalassemia.

Genetics in medicine : official journal of the American College of Medical Genetics, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.